Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases

Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity

“…4,5 Therefore, in addition to pegylated liposome-encapsulated form of DOX, the use of non-pegylated liposomal (NPL)-DOX is also predominant in chemotherapy. 6 NPL-DOX as a component of the R-CHOP regimen is a highly effective treatment in patients with diffuse large B cell lymphoma and pre-existing cardiac diseases. 6 Though the median left ventricular ejection fraction did not change after chemotherapy, the cardiac events were, indeed, observed in 36% of patients in this cardiac high-risk group; most of these events occurred in the follow-up and, in some cases, a relationship to chemotherapy remains uncertain.…”

“…6 NPL-DOX as a component of the R-CHOP regimen is a highly effective treatment in patients with diffuse large B cell lymphoma and pre-existing cardiac diseases. 6 Though the median left ventricular ejection fraction did not change after chemotherapy, the cardiac events were, indeed, observed in 36% of patients in this cardiac high-risk group; most of these events occurred in the follow-up and, in some cases, a relationship to chemotherapy remains uncertain. A decreased left ventricular ejection fraction was observed in 28% of patients without a greater frequency in the group of patients with pre-existing reduced left ventricular ejection fractions.…”

“…5,6 However, so far, the replacement test of PLD in CHOP regimens has focused on patients with senile decay, and clinical trials are still under way for general patient trials. 26,27 In these clinical trials of elderly patients and patients with cardiac dysfunction, a very noteworthy situation is that the doses used are lower than the conventional dose of DOX, ranging from 25 In this study, we used the Apt-Lip-DOX delivery system, with PEG involved as a coupling agent rather than on the outer layer as with PLD ( Figure S3C) coupled with aptamer.…”

A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient

“…Our patient presented with high risk disease. The first line therapy for this type of high risk DLBCL recommended by the National Comprehensive Cancer Network is R-CHOP or dose-adjusted R-EPOCH (4)(5)(6)(7)(8)23,24). However, about 50% of patients are above 60 years old at the time of diagnosis.…”

Analysis of the Treatment of Diffuse Large B-Cell Lymphoma in Patients with Preexisting Systolic and/or Diastolic Dysfunction at Moffitt Cancer Center

“…A small (25 patients) recent German retrospective study assessing the same patient population with DLBCL and preexisting cardiac dysfunction who were receiving R-CHOP, reported an incidence of 36% of major cardiac events in this high-risk population [18]. Another recent retrospective study done by DLBCL patients over 65-years-old suggests that elderly patients experience meaningful PFS with anthracycline-containing regimens, but one third experienced toxicity requiring treatment modifications [19].…”